Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies

被引：2
|
作者：
Zipp, Lisa
Saliba, Rima M.
Valverde, Rosamar [1 ]
Okoroji, Grace-Julia
Korbling, Martin
Samuels, Barry I.
Abruzzo, Lynne V. [2 ]
Alousi, Amin M.
Andersson, Borje S. [1 ]
Hosing, Chitra M.
Erwin, Bill
Anderlini, Paolo [1 ]
Popat, Uday R.
Kebriaei, Partow
Macapinlac, Homer A.
Champlin, Richard [1 ]
Khouri, Issa F.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.2005.2005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：875 / 876
页数：2
相关论文
共 50 条
  • [21] A comparison of beam and yttrium 90 ibritumomab tiuxetan (Zevalin®) in addition to beam (Z-BEAM) in older patients undergoing autologous stem cell transplant (ASCT) for B-cell lymphomas:: Impact of radioimmunotherapy on transplant outcomes.
    Krishnan, Amrita Y.
    Nademanee, Auayporn
    Raubitschek, Andrew
    Fung, Henry C.
    Molina, Arturo
    Yamauchi, David
    Falk, Peter M.
    Spielberger, Ricardo
    Palmer, Joycelynne
    Tsai, Ni Chun
    Schriber, Jeffrey
    Forman, Stephen J.
    BLOOD, 2006, 108 (11) : 865A - 866A
  • [22] OUTCOMES AFTER 90YTTRIUM-IBRITUMOMAB TIUXETAN-BEAM IN DIFFUSE LARGE B-CELL LYMPHOMA: A META-ANALYSIS
    Auger, S.
    Duny, Y.
    Daures, J. P.
    Quittet, P.
    HAEMATOLOGICA, 2014, 99 : 697 - 697
  • [23] Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial
    Briones, Javier
    Novelli, Silvana
    Garcia-Marco, Jose A.
    Tomas, Jose F.
    Bernal, Teresa
    Grande, Carlos
    Canales, Miguel A.
    Torres, Antonio
    Moraleda, Jose M.
    Panizo, Carlos
    Jarque, Isidro
    Palmero, Francisca
    Hernandez, Miguel
    Gonzalez-Barca, Eva
    Lopez, Dulce
    Caballero, Dolores
    HAEMATOLOGICA, 2014, 99 (03) : 505 - 510
  • [24] Outcomes after 90Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis
    Auger-Quittet, Sophie
    Duny, Yohan
    Daures, Jean-Pierre
    Quittet, Philipe
    CANCER MEDICINE, 2014, 3 (04): : 927 - 938
  • [25] 90Y-Ibritumomab tiuxetan (Zevalin®) in combination with high-dose therapy (HDT) followed by autologous stem cell transplant (ASCT) may improve survival in patients with poor-risk follicular lymphoma (FL) and diffuse large B-Cell lymphoma (DLBCL):: Results of a retrospective comparative analysis.
    Nademanee, Auayporn-P.
    Krishnan, Amrita
    Tsai, Nicole
    Palmer, Joycelynne
    Molina, Arturo
    Fung, Henry C.
    Yamauchi, David
    Kogut, Neil Martin
    Forman, Stephen J.
    Raubitschek, Andrew
    BLOOD, 2006, 108 (11) : 102A - 102A
  • [26] Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma
    Shimoni, Avichai
    Zwas, S. Tzila
    Oksman, Yakov
    Hardan, Izhar
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Avigdor, Abraham
    Ben-Bassat, Isaac
    Nagler, Arnon
    EXPERIMENTAL HEMATOLOGY, 2007, 35 (04) : 534 - 540
  • [27] High-dose rituximab in combination with autologous stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma
    Shi, Yi-Fen
    Zhou, Shu-Juan
    Sun, Lan
    Yu, Kang
    Chen, Yi
    MEDICINA CLINICA, 2020, 155 (06): : 235 - 241
  • [28] Dose finding trial of Yttrium 90 ibritumomab tiuxetan (90YIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Flinn, I. W.
    Kahl, B. S.
    Frey, E. C.
    Bianco, J. A.
    Hammes, R. J.
    Webb, J.
    Swinnen, L. J.
    Sgouros, G.
    Wahl, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 430S - 430S
  • [29] Immunologic Recovery Following Consolidation with 90Yttrium Ibritumomab Tiuxetan ( Zevalin®)- BEAM and Autologous Stem Cell Transplantation for Transformed B Cell Non-Hodkgin's Lymphoma
    Wondergem, Marielle J.
    Westers, Theresia M.
    Visser, Otto
    Zijlstra, Josee M.
    Zweegman, Sonja
    Chamuleau, Martine E. D.
    BLOOD, 2014, 124 (21)
  • [30] 90Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory. follicular lymphoma. GELA phase II study
    Gisselbrecht, Christian
    Decaudin, Didier
    Mounier, Nicolas
    Tilly, Herve
    Ribrag, Vincent
    Sebban, Catherine
    Milpied, Noel
    Morschhauser, Franck
    Coiffier, Bertrand
    Le Gouill, Steven
    Lederlin, Pierre
    Delarue, Richard
    Laurent, Guy
    Bosly, Andre
    BLOOD, 2007, 110 (11) : 14A - 15A
12345